Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
Authors
Keywords
Immune checkpoint inhibitors, Neurological adverse events, Anti-PD-1, Anti-CTLA-4, Encephalitis, Meningitis, Polyneuropathy, Myositis
Journal
Current Neurology and Neuroscience Reports
Volume 18, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-02-01
DOI
10.1007/s11910-018-0810-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
- (2017) Ralf Gutzmer et al. EUROPEAN JOURNAL OF CANCER
- Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors
- (2017) D. Makarious et al. EUROPEAN JOURNAL OF CANCER
- Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy
- (2017) W. Boisseau et al. EUROPEAN JOURNAL OF CANCER
- Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
- (2017) S. Cuzzubbo et al. EUROPEAN JOURNAL OF CANCER
- Immune mediated neuropathy following checkpoint immunotherapy
- (2017) Yufan Gu et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder
- (2017) Elaine Chang et al. JOURNAL OF IMMUNOTHERAPY
- Severe Ocular Myositis After Ipilimumab Treatment for Melanoma
- (2017) Anna Pushkarevskaya et al. JOURNAL OF IMMUNOTHERAPY
- Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma
- (2017) Yu-Hsiu Chen et al. MEDICINE
- Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients
- (2017) Bella H.V. Nguyen et al. MELANOMA RESEARCH
- Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan
- (2017) Shigeaki Suzuki et al. NEUROLOGY
- Myasthenia triggered by immune checkpoint inhibitors: New case and literature review
- (2017) Natalia L. Gonzalez et al. NEUROMUSCULAR DISORDERS
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis
- (2017) James Larkin et al. ONCOLOGIST
- Pembrolizumab-induced myasthenia gravis: A fatal case report
- (2017) Katherine L March et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma
- (2016) H. Vallet et al. ANNALS OF ONCOLOGY
- Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature
- (2016) L. Spain et al. ANNALS OF ONCOLOGY
- Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm
- (2016) C.L. Haddox et al. ANNALS OF ONCOLOGY
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- (2016) A. M. Menzies et al. ANNALS OF ONCOLOGY
- Myasthenic crisis and polymyositis induced by one dose of nivolumab
- (2016) Toshihiro Kimura et al. CANCER SCIENCE
- Neurologic complications of immune checkpoint inhibitors
- (2016) Andreas F. Hottinger CURRENT OPINION IN NEUROLOGY
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
- (2016) Lisa Zimmer et al. EUROPEAN JOURNAL OF CANCER
- Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain–Barré syndrome: a case report
- (2016) Ryota Tanaka et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease
- (2016) Lara V. Maul et al. JOURNAL OF IMMUNOTHERAPY
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
- (2016) Scott Antonia et al. LANCET ONCOLOGY
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Severe inflammatory myositis in a patient receiving concurrent nivolumab and azacitidine
- (2016) Lalit Saini et al. LEUKEMIA & LYMPHOMA
- Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab
- (2016) K. H. Vincent Lau et al. MUSCLE & NERVE
- Myasthenia gravis exacerbation associated with pembrolizumab
- (2016) Julia Zhu et al. MUSCLE & NERVE
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy
- (2016) Marie-Florence de Maleissye et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Case of Nivolumab-Induced Myositis
- (2016) E. Fox et al. ONCOLOGIST
- Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer
- (2016) Tanya J. Williams et al. JAMA Neurology
- Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma
- (2016) L. Khoja et al. Cancer Immunology Research
- Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma
- (2016) Justin LaPorte et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody
- (2016) Mehmet Asim Bilen et al. Journal for ImmunoTherapy of Cancer
- Meningoencephalitis Following Ipilimumab Administration in Metastatic Melanoma
- (2015) Matthew K. Stein et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma
- (2015) Douglas B. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab-Associated Bilateral Optic Neuropathy
- (2015) Oliver L. Yeh et al. JOURNAL OF NEURO-OPHTHALMOLOGY
- Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer
- (2015) Aaron I. Loochtan et al. MUSCLE & NERVE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bilateral Facial Palsy following Ipilimumab Infusion for Melanoma
- (2015) Ashley L. Altman et al. OTOLARYNGOLOGY-HEAD AND NECK SURGERY
- Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
- (2015) Alexander Faje Pituitary
- Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma
- (2015) C. Maurice et al. Cancer Immunology Research
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Lambrolizumab induced central nervous system (CNS) toxicity
- (2014) Jacob J. Mandel et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma
- (2014) Edward J Gettings et al. Multiple Sclerosis Journal
- Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma
- (2014) B. Liao et al. NEURO-ONCOLOGY
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- Myosite orbitaire associée à un traitement par ipilimumab
- (2013) M. Lecouflet et al. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE
- Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab
- (2013) Jeffrey S. Weber et al. CANCER
- Limbic encephalitis: a clinical-radiological comparison between herpetic and autoimmune etiologies
- (2013) B. Oyanguren et al. EUROPEAN JOURNAL OF NEUROLOGY
- Multifocal radiculoneuropathy during ipilimumab treatment of melanoma
- (2013) Georgios Manousakis et al. MUSCLE & NERVE
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- (2013) Caroline J. Voskens et al. PLoS One
- MECHANISMS IN ENDOCRINOLOGY: Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review
- (2012) A. Juszczak et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Severe meningo-radiculo-nevritis associated with ipilimumab
- (2012) Flavie Bompaire et al. INVESTIGATIONAL NEW DRUGS
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- A Severe Case of Ipilimumab-Induced Guillain-Barré Syndrome Revealed by an Occlusive Enteric Neuropathy
- (2012) Caroline Gaudy-Marqueste et al. JOURNAL OF IMMUNOTHERAPY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient
- (2011) S. Wilgenhof et al. ANNALS OF ONCOLOGY
- Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma
- (2011) Michela Maur et al. JOURNAL OF CLINICAL ONCOLOGY
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- Safety and clinical activity of ipilimumab in melanoma patients with brain metastases
- (2011) Jeffrey S. Weber et al. MELANOMA RESEARCH
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started